Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Vifor Pharma
Vifor Pharma
Activities:
Manufacturing
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies
The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Vifor Pharma to propose Åsa Riisberg for board of directors
Riisberg holds a MSc in Financial Economics and Business Administration from Stockholm School of Economics
Ingredients
Vifor Pharma enters Chinese joint venture with Fresenius Kabi
Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Finance
Vifor Pharma enters commercial diabetes collaboration in the US
The Swiss pharma company will work with US-based Janssen to jointly commercialise INVOKANA (canagliflozin) in the US to address complications of type 2 diabetes
Drug Delivery
PIVOTAL trial confirms long-term safety and efficacy of IV iron dosing
The long-term safety and efficacy of intravenous iron dosing has been confirmed allowing higher Ferritin concentration and transferrin saturation in patients undergoing haemodialysis
Recruitment
Vifor pharma announces management changes
Media
Vifor Pharma proposes Jacques Theurillat as board member
Pharmaceutical
Kissei to market Avacopan in Japan for Vifor Pharma
Vifor Fresenius Medical Care Renal Pharma has granted Japanese pharmaceutical company, Kissei, exclusive rights to develop and commercialise Avacopan in Japan
Subscribe now